News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov
10
- Multi-dosing portion of Fusion's Phase 1 study of FPI-1434 on track to be initiated in Q4 2020 - Company executes collaboration agreement with AstraZeneca to grow pipeline of next-generation...
-
Nov
02
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of...
-
Nov
02
Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies Fusion to Host a Conference Call at...
-
Sep
29
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of...
-
Sep
10
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...
